Datopotamab deruxtecan FDA Approval Status
FDA Approved: No
Generic name: datopotamab deruxtecan
Company: AstraZeneca and Daiichi Sankyo
Treatment for: Non-Small Cell Lung Cancer
Datopotamab deruxtecan is a specifically engineered TROP2-directed DXd antibody drug conjugate in development for the treatment of non-small cell lung cancer.
Development timeline for datopotamab deruxtecan
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.